ArticleDrug delivery and translational research2025
Effects of beta and gamma radiation sterilization on growth factor-loaded nanoparticles: an innovative approach for osteoarticular disorders treatment.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Plasma-Depleted Lyophilized Porcine Platelet Lysate as an Alternative to Fetal Bovine Serum in Cell Culture.Life (Basel, Switzerland) · 2025Article
- Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases.Journal of nanobiotechnology · 2025Review
- In Situ Forming Poloxamer-Based Thermo-Sensitive Hydrogels for Ocular Application: A Focus on the Derivatives 407 and 188.Gels (Basel, Switzerland) · 2025Review
- Surface Functionalization of Nanoparticles for Enhanced Electrostatic Adsorption of Biomolecules.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of various diseases, including osteoarticular conditions, is increasing as the world's population ages. These disorders lead to degeneration of bones and joints, diminishing the quality of life of the geriatric population and imposing a significant economic burden on healthcare systems. The aim of the present study is to sterilize nanostructured lipid carriers (NLCs) loaded with vascular endothelial growth factor 165 (VEGF165) and platelet-derived growth factorBB (PDGF-BB) without compromising their properties to improve osteoarticular disease prognosis. Therefore, two methods of sterilization using ionizing radiation - beta radiation and gamma radiation - and two different doses - 12 kGy and 25 kGy - were investigated. Subsequently, the study evaluated whether the sterilization process had any effect on the nanoparticles and encapsulated growth factors by assessing their physicochemical properties, toxicity, release profiles and bioactivity. The treatment with 12 kGy of beta radiation successfully sterilized the batch of nanoparticles without inducing any changes in the physicochemical properties. In addition, the release profile of VEGF165 remained unchanged, although a slight decrease was observed in the case of PDGF-BB. The biological activity of the growth factors showed a slight decrease, with the most effective concentrations being 5 ng/mL for VEGF165 and 50 ng/mL for PDGF-BB. Taken together, these findings suggest that the nanoparticles loaded with VEGF165 and PDGF-BB can be successfully sterilized while retaining both their properties and biological activity. These nanoparticles may offer a promising new approach for the treatment of osteoarticular diseases by enhancing vascularization and promoting cellular proliferation in the affected tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.